Development of Human Mast Cells from Hematopoietic Stem Cells within a 3D Collagen Matrix: Effect of Stem Cell Media on Mast Cell Generation

Tahereh Derakhshan,1 Rudra Bhowmick,1 Jerry W. Ritchey,2 and Heather Gappa-Fahlenkamp†1

1School of Chemical Engineering, Oklahoma State University, 420 Engineering North, Stillwater, OK 74078, USA
2Department of Veterinary Pathobiology, Center for Veterinary Health Sciences, Oklahoma State University, 250 McElroy Hall, Stillwater, OK 74078, USA

Correspondence should be addressed to Heather Gappa-Fahlenkamp; heather.fahlenkamp@okstate.edu

Received 26 February 2018; Revised 20 April 2018; Accepted 27 May 2018; Published 11 July 2018

1. Introduction

Release of preformed mediators and expression of diverse molecules have placed mast cells (MCs) among the foremost inducers of allergic responses and regulators of innate and adaptive immunity [1, 2]. MCs are abundant in tissue near surfaces exposed to the external environment, and their number and distribution change markedly during immune responses [3–5]. During immunoglobulin E- (IgE-) dependent responses, cross-linking of the FceRI/IgE complexes leads to MC activation and degranulation of a wide range of bioactive products, including histamine [2]. The mediators increase vascular permeability and recruit leukocytes to the site of insult, resulting in hyperemia and edema, the cardinal symptoms of acute inflammation [6]. MC mediators can exert multiple effects, such as extracellular matrix remodeling in fibrosis or degradation during early events of angiogenesis, giving them the potential to be involved in the pathogenesis of a variety of disorders [7–9].

Although MCs are not normally present in circulation, they can be obtained from progenitor cells in the presence of T cell-derived cytokines and fibroblast-derived stem cell factor (SCF) [10–12]. CD133 and CD34 antigens are markers for primitive progenitor and hematopoietic stem cell (HSC) populations [13, 14]. Previous studies have shown that upon treatment with SCF, interleukin- (IL-) 3, and IL-6, CD133+ HSCs isolated from various sources, including cord blood and peripheral blood, can differentiate into MCs under a two-dimensional (2D) culture condition [15, 16]. The growth, phenotype, and function of the generated MCs can be altered by the culture media supplements [17–19]. As an instance, the addition of serum to the media from the
beginning of culture can result in a low number of mature MCs with reduced FcεRI expression, while its addition at later weeks of the culture period promotes the expression of FcεRI and histamine release upon activation [20, 21]. Although the generation of MCs under 2D culture conditions provided a source for human MC studies, they have been considered as immature MCs or “incomplete representatives of mature MCs” due to the lack of in vivo microenvironmental conditions that may affect MC phenotypic and functional characteristics [1, 22]. Since MCs mature and interact with other cells within tissue, providing a condition that better mimics the in vivo three-dimensional (3D) milieu would be of greater relevance for studying MC responses and immune-regulatory roles. In fact, interaction between MCs and extracellular matrix components can affect MC behavior and influence their biological functions [23]. Therefore, the first objective of this study was to demonstrate the generation of MCs within a 3D collagen matrix, which provides the conditions for investigating the cellular interactions that are not possible to examine within a conventional 2D culture system.

MCs are located near blood or lymphatic vessels in proximity to fibroblasts that are a principal cellular component of tissue [22]. Previous studies have shown that the cross talk between MCs, fibroblasts, and endothelial cells (ECs) mediates various physiological and pathological processes [24, 25]. Besides the release of growth factors that are essential for MC survival and maturity, direct interaction between fibroblasts and ECs can regulate MC development [26–28]. Therefore, incorporation of fibroblasts and ECs into the 3D tissue model allows the transmission of similar signaling molecules that HSCs may receive during differentiation into MCs from neighboring cells in vivo. However, for the creation of such a tissue-engineered model, there are no universal media that support the overall growth of MC precursors and the abovementioned ancillary cells. In fact, selecting the appropriate culture media is determinant to the success of a coculture system. Since each cell type has specific growth requirements, a suitable media that regulates their survival needs to be determined. Previous studies have shown the expansion of CD34+ HSCs or their differentiation into MCs by using cytokine-supplemented and serum-free media [29–32]. However, most studies with fibroblasts and ECs use media with serum not specific for HSC growth and differentiation [33–35]. Therefore, the second objective of the current study was to determine a medium that would support the generation of functional MCs from HSCs, as well as one that would support the normal characteristics of fibroblasts and ECs. Having an understanding of the effect of culture media on each individual cell type is an important first step needed before the development of a coculture model with multiple cell interactions.

2. Material and Methods

2.1. Antibodies and Reagents. M199 and StemPro®-34 SFM culture media were purchased from Life Technologies (Carlsbad, CA). HPGM™ and StemSpan™ SFEM cell culture media were purchased from Lonza (Walkersville, MD) and STEMCELL Technologies (Vancouver, Canada), respectively. Human SCF, IL-6, and IL-3 were purchased from ProSpec (Rehovot, Israel) or PeproTech (Rocky Hill, NJ). Defined HyClone fetal bovine serum (FBS) was purchased from GE Healthcare Life Sciences (Logan, UT). Human fibroblasts treated with mitomycin C were purchased from Merck Millipore (Billerica, MA), while human umbilical vein ECs were purchased from PromoCell (Heidelberg, Germany). Anti-human fluorochrome-conjugated CD117/c-kit (clone 104D2), FcεRI (clone CRA-1), and CD31 (clone WM59), and their isotype controls, Ms IgG1 (clone MOPC-21) and Ms IgG2b (clone MPC-11), were purchased from BioLegend (San Diego, CA). Anti-human fluorochrome-conjugated CD90 (clone 5E10), its isotype, Ms IgG1 (clone MOPC-21), and mouse anti-human tryptase (clone AA1) were purchased from Abcam (Cambridge, MA). Mouse anti-human chymase (clone B7) and the secondary antibody goat anti-mouse IgG1 were from Chemicon International Inc. (Temecula, CA) and Santa Cruz Biotechnology (Dallas, TX), respectively.

2.2. Cell Culture

2.2.1. Hematopoietic Stem Cell (HSC) Culture. CD133+ cells were obtained from human peripheral blood mononuclear cells (PBMCs). PBMCs were isolated from fresh leukocyte preparations (obtained from the Oklahoma Blood Institute; Oklahoma City, OK) by the Ficoll-Paque density separation method (GE Healthcare; Pittsburgh, PA). CD133+ cells were isolated from PBMCs using a magnetic separation kit (MACS Miltenyi Biotec; Bergisch Gladbach, Germany).

CD133+ cells were cultured and differentiated within a 3D collagen gel. For this, a 2 mg/ml collagen solution was prepared by modifying a previous protocol [36] using 64.5 vol% of 3.1 mg/ml type 1 bovine collagen (Advanced BioMatrix, Carlsbad, CA), 8.1 vol% 10x M199, 13.3 vol% 0.1 N NaOH, and 14.1 vol% PBS. CD133+ cells were mixed with the collagen solution (5.1 x 10^5 cells/ml) and added to the cell culture plates. Following gel formation (45 min), media were added to the samples and the samples were incubated for seven weeks with media changes once a week. Media were supplemented with human SCF (100 ng/ml), IL-6 (50 ng/ml), and IL-3 (1 ng/ml) for the first three weeks of culture. The CD133+ cells were monitored weekly and characterized on the seventh week of culture. In order to study the effect of serum on the growth and differentiation of CD133+ cells, FBS (10%, v/v) was added at three different time points: (i) from the day of seeding until the end of the seventh week (Ser1–7), (ii) on the seventh week only (Ser7), and (iii) on the first, second, and seventh week (Ser1, 2, and 7). In all cases, media was changed once a week.

2.2.2. Fibroblast and Endothelial Cell (EC) Culture. Cell culture plates (24 wells, area 1.9 cm², Greiner Bio-One, Monroe, NC) were coated with fibronectin (25 μg/ml in phosphate-buffered saline, PBS) for 2 h before cell seeding. Fibroblasts and ECs were cultured separately in serum-free StemSpan, StemPro, and HPGM. M199 containing 1 vol% PSG (penicillin, streptomycin, and L-glutamine) was used as the “standard media” [33, 34, 37]. ECs were cultured in media with
and without the addition of FBS. Fibroblast and ECs were cultured at 35,000 cell/cm² and 12,000 cell/cm² density, respectively, at 37°C, 5% CO₂ (defined here as “standard conditions”) with media changes on every other day until confluent and ready for testing.

2.3. Characterization of Mast Cells (MCs)

2.3.1. Yield and Granule Formation. In order to determine the number of generated viable cells, the collagen matrix was digested after incubation with 2 mg/ml of collagenase D (Roche Applied Science; Indianapolis, IN). The harvested cells in the digested solution were counted by a hemocytometer and the number of viable cells was determined by trypan blue exclusion. The cell yield was calculated as the ratio of the number of viable cells harvested to the number of cells seeded. Cytosolic granule formation was determined by Wright-Giemsa staining using an automated stainer (Ames Hema-Tek Stainer).

2.3.2. Expression of Phenotypic Markers. Expression of c-kit and FceRI was assessed by flow cytometry. After seven weeks of culture, the expression of FceRI was stabilized by incubating the cells for 24 h with myeloma IgE (2 μg/ml, Merck Millipore). Following collagenase D digestion of the matrix, the cells were collected, stained using anti-c-kit and anti-FceRI antibodies or relevant isotype controls, and analyzed by flow cytometry. Dead cells were excluded by PI staining. For immunocytochemical staining of tryptase and chymase granules, the cells were collected from the matrix and fixed by using a fixation/permeabilization solution kit (BD Biosciences; CA). After incubation with a blocking solution containing 10% goat serum (v/v%, Gibco; CA) for 1 h, the cells were incubated with primary antibodies against tryptase or chymase or isotype control. Following this, a secondary antibody was added, and incubated for 30 min at room temperature. The cells were incubated for at least 1 h in the staining buffer containing 0.2% bovine serum albumin (BSA), prior to staining with anti-c-kit antibody and analysis by flow cytometry.

2.3.3. Activation and Histamine Release. At seven weeks post-seeding, the function of the generated cells was examined by cross-linking the FceRI receptors by IgE and anti-IgE. Activation was performed for cells within the matrix and for cells removed from the matrix. Cells were sensitized with 15 μg/ml myeloma IgE (Athens Research & Technology; Athens, GA) in complete media for 24 h and rinsed three times prior to activation with various concentrations of anti-IgE (Chemicon International Inc.; Temecula, CA) in Tyrode’s solution (Boston BioProducts; Ashland, MA) supplemented with SCF and IL-6 for 1 h. For measuring the cellular histamine, cells were lysed by freeze-thaw cycles in water and sonicated for 5 min. Histamine was quantified using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Labor Diagnostika Nord; Nordhorn, Germany). The percentage of histamine release is determined by taking the ratio of the total amount of histamine released by the cells to the total histamine content initially in the cells. In addition, the spontaneous amount of histamine released by the cells under normal conditions was subtracted from the total amount released. For the samples activated within the matrix, the total amount of histamine released by the cells is determined by measuring the amount of histamine in the media and the gel solution.

2.4. Characterization of Fibroblast and Endothelial Cells (ECs)

2.4.1. Proliferation. To measure cell proliferation, fibroblasts and ECs were fluorescently labeled with CellTracker or CellTrace (Life Technologies) prior to culture. The stained cells were harvested by trypsinization, and the fluorescent intensities were measured by flow cytometry. As cells divide, the fluorescent probe is split evenly between the daughter cells and the mean fluorescent intensity (MFI) per cell decreases. As a control for nondividing cells, fibroblasts were stained with CellTrace and analyzed before seeding. Dead cells were stained with propidium iodide (PI, Life Technologies) [38]. All the cell dyes were used following the manufacturer’s protocols.

2.4.2. Expression of Surface Receptors and Secretion of Mediators. Expression of CD90 by fibroblasts and CD31 by ECs was determined by flow cytometry. Trypsinized cells were collected and stained with anti-CD90 or anti-CD31 antibodies or their isotype controls (45 min, 4°C). Dead cells were excluded by PI staining. To determine the secretion of SCF and IL-6 by fibroblasts and ECs, culture supernatants were collected and analyzed by commercial ELISA kits (PeproTech).

2.5. Statistical Analysis. Experimental results are expressed as mean ± SD of three samples. One-way analysis of variance (ANOVA) was selected to determine significant differences between groups. Tukey’s or Student’s t-test was used for pairwise comparison of groups or between two groups, respectively. A value of p < 0.05 was considered significant.

3. Results and Discussion

3.1. Effect of Culture Media on the Generation of Mast Cells (MCs) from CD133⁺ Hematopoietic Stem Cells (HSCs). M199, our standard media for EC culture that was also used for fibroblasts, either with serum added from the beginning or in the last week of culture, did not support MC generation and survival, as verified by microscopy, viability, and flow cytometry analyses. From the first week, most cells in all the media, except for HPGM (Ser7), formed colonies as a sign of cell generation.

During differentiation, the morphology of MC progenitors sequentially change, until they mature into MCs. Initially, progenitor cells (blasts) have a high nuclear to cytoplasm ratio, and then gradually acquire granules that can be stained to form metachromatic blasts. The atypical type II MCs (called the promastocytes) have bi- or polylobed nuclei, which are oval or eccentrically located, and often possess hypogranulated cytoplasm. At the end of the developmental stage, the mature, typical MCs are formed, which are round or oval with granulated cytoplasm, low nuclear to cytoplasm ratio, and a centrally positioned, round nucleus [39–41]. As shown in
Figure 1(a), in the seventh week of culture for all the test media, the cells were mostly round or oval. Except for a few larger cells in the StemPro (Ser1–7) medium, the size of the generated cells in all the test media were in the range of in vivo MCs (8–20 μm) [23, 42]. As shown in Figure 1(b), the generated cells exhibited metachromatic cytoplasmic granules following Wright-Giemsa staining, which is a morphological characteristic of MCs [16]. In StemPro, some cells were hypogranulated, as shown by the black arrow. (c) Cell yields in the culture media. Cell yield is defined as the ratio of the cells collected at the end of the culture period to the seeded cells. (d) Histamine granule formation in the generated cells. Data are represented as mean ± SD; n = 3. * indicates p < 0.05.

Figure 1(a), in the seventh week of culture for all the test media, the cells were mostly round or oval. Except for a few larger cells in the StemPro (Ser1–7) medium, the size of the generated cells in all the test media were in the range of in vivo MCs (8–20 μm) [23, 42]. As shown in Figure 1(b), the generated cells exhibited metachromatic cytoplasmic granules following Wright-Giemsa staining, which is a morphological characteristic of MCs [16]. In StemPro (Ser1–7), 30% of the cells were hypogranulated, as shown by the black arrow in Figure 1(b). The results indicate that the cells generated from the MC precursors in the collagen matrix had the morphology of typical, mature and immature MCs, with distinct promastocytic characteristics.

As shown in Figure 1(c), there was no significant difference in cell yields for the media tested with serum from the first week of culture. For the media with serum added in the last week, there was a significantly greater cell yield in StemSpan compared to StemPro (3.1 ± 0.8-fold, p < 0.05). For StemSpan (Ser7), the number of cells at termination of culture was 2.2 ± 0.1-fold higher than that of CD133+ cells initially seeded in the collagen matrix, which is similar to a 2D culture system that used the same culture medium and generated 3.2 ± 1-fold that of the seeded cells [16].

The histamine content of MCs in vivo depends on their anatomic location and subtype. The histamine level in MCs varies from 0.8–12.5 pg/cell to 0.8–5 pg/cell in lung and skin,
respectively [42–44]. In this work, the differentiated cells in all but StemPro (Ser1–7) and HPGM media had similar histamine content to that of in vivo MCs, and varied between 0.6 and 2.3 pg/cell. Cells cultured in StemPro (Ser1–7) had lower histamine content (0.28 ± 0.21 pg/cell), as verified by the presence of some hypogranulated cells in the Wright-Giemsa-stained sample. MCs generated in StemSpan (Ser7) had significantly greater histamine content compared to all other test media (p < 0.05, Figure 1(d)). The histamine content of the MCs generated in a 2D culture system using the StemSpan medium was 15.5 ± 5.3 pg/cell [16], which is higher than the histamine content observed in the in vivo MCs. However, this was not the case for the MCs generated within the collagen matrix using the StemSpan medium in this study, with histamine content within the range of in vivo observations.

In addition to morphology and granule formation, immunophenotypical markers are used to distinguish MCs from other cell types. MCs, basophils, eosinophils, dendritic cells, macrophages, and ECs are known to have common precursor cells [45–48], but these cell types vary in their immunophenotype and expression of other markers. MCs, progenitor and HSCs, and ECs all express c-kit [49]. HSCs, ECs, eosinophils, and cells of monocytic lineages lack histamine granules and possess significantly different morphology [50]. Basophils express histamine and FcεRI, but previous studies have shown that they do not express c-kit [51, 52]. Out of these cell populations, only mature MCs possess histamine granules and express both FcεRI and c-kit receptors, making these markers useful to define the MC phenotype. As shown in Figure 2, in the media where serum was added at the first week of culture, there was no significant

Figure 2: Expression of c-kit and FcεRI by generated cells from CD133+ hematopoietic stem cells (HSCs) in a collagen matrix after seven weeks in culture. The figure shows the gating scheme (top panel) and representative density plots of the isotype control and expression of phenotypic markers (middle and bottom panel, resp.). More than 90% of the cells are gated in the bottom left corner of the isotype density plots. The bar graphs show the percentage of c-kit expression. Data are represented as mean ± SD; n = 3. * indicates p < 0.05.
difference in c-kit expression; however, there was a $1.6 \pm 0.1$- and $1.8 \pm 0.1$-fold increase in c-kit density (MFI, $p < 0.05$) for StemSpan and HPGM compared to StemPro, respectively. Similarly, for media with serum added in the last week of culture, there was no significant difference in c-kit expression, with $1.3 \pm 0.2$ times more c-kit density (MFI, $p < 0.05$) in StemSpan compared to StemPro. A 2D culture method that used StemSpan media also showed a high percentage of c-kit-positive cells (88.3 ± 2.2%) [16]. The expression of FceRI was similar for all the test media (10–23% on average); however, the FceRI density (MFI) was 1.4–2.3 times higher ($p < 0.01$) in StemSpan (Ser1–7) than for the other media. The expression of FceRI was lower in comparison with 2D culture systems that used StemSpan or StemPro media [16, 53]. Other reports have shown that incubation with IgE antibody modulates the expression of FceRI and can contribute to its detection [54, 55]. For all the test media, IgE was added to the cells in the collagen matrix, prior to collecting the cells and measuring FceRI expression. The lower expression could be due to the binding of IgE with the matrix, resulting in less IgE available to interact with the matrix-embedded cells, compared to the other system with cells in suspension.

3.2. Effect of Serum on Mast Cell (MC) Development. Our results show that the addition of serum to the culture media affected various characteristics of the HSC-derived cells, such as morphology, proliferation of HSCs, cell surface marker expression, and histamine content of the generated cells (Figures 1–3). Other studies have shown that MCs in serum-supplemented media had multilobed nuclei or macrophage-like morphology, in contrast with the cells in serum-free media [20, 56]. The results from our work also indicate that the timing of adding serum to the culture media can affect the morphology and internal structure of the generated cells, which could be related to the stage of cellular development. When serum was added in the first two and last weeks of culture, more cells had bi- (30%) or multinucleated (10%) morphology in comparison to when serum was added only in the last week of culture, with 8% and 2% bi- and multinucleated cells, respectively (Figure 3(a)). Furthermore, similar to other serum-supplemented cell cultures [57, 58], the proliferation of progenitor cells increased (by 72% for StemSpan medium) when serum was added from the beginning of culture, compared to the last week, for a seven-week culture period ($p < 0.05$, Figure 3(b)). The results indicate...
that although serum induces cell proliferation, the addition of serum in the beginning of culture can delay the morphologic change from promastocytes to mature MCs.

Moreover, serum appeared to have an inhibitory effect on histamine content. For MCs generated in StemSpan and StemPro, the histamine content was more than two-fold higher when serum was added in the last week of culture, compared to the beginning of culture ($p < 0.05$, Figure 1(c)). As shown in Figure 3(c), when serum was added from the beginning of culture, the inhibitory effect of the serum on the formation of histamine granules was mitigated.

As shown in Figure 3(d), compared to the samples that contained serum throughout culture, excluding serum after the second week enhanced the c-kit expression, verifying that serum suppressed MC development. Although the effect of serum on FcεRI expression was not significant ($p > 0.05$), there was a significant increase in the receptor density ($1.6\pm0.2$-fold, $p < 0.05$) on the surface of cells cultured in StemSpan (Ser1, 2, and 7) compared to StemSpan (Ser1–7). These results show that not only does serum affect the cellular immunophenotype, but the timing of its addition can also alter the expression and the density of the cell surface receptors. Previous studies have shown that the addition of serum to the media from the beginning of culture reduces the expression or the density of c-kit, while increasing the expression of myeloid markers (such as CD14, CD11b, and CD13) [20, 56]. These studies suggested that serum factors can induce the generation of other cell types and delay the development of MCs. However, a serum-free media could also result in lower FcεRI expression and abolish MC activation [20].

### 3.3. Effect of Culture Media on Fibroblasts

As shown in Figure 4(a), fibroblasts displayed normal, elongated morphology in all the test media. The test media are typically not used to culture fibroblasts, but our results indicate that the cells show normal morphology in all the media.

The cell yields varied across the test media (Figure 4(b)). StemSpan showed a higher cell yield (more than two-fold) than StemPro and HPGM ($p < 0.05$, Figure 4(b)). As shown in Figure 4(c), (i), cells in all the media divided at least once in comparison with the control, nondividing cells. The MFI of the CellTrace CFSE-stained cells in the test media were higher than M199 ($p < 0.05$), showing lower proliferation. StemPro did not support the proliferation of fibroblasts as much as the other test media, as specified by the higher MFI of stained cells ($p < 0.05$, Figure 4(c), (ii)). Therefore, fibroblasts were more proliferative and higher in number in StemSpan than other media tested.

Fibroblasts cultured in all the test media expressed CD90 (a phenotypic marker of fibroblasts [59]), as shown in Figure 4(d), (i) and (ii). CD90 expression was higher for fibroblasts in StemPro compared to StemSpan and HPGM ($p < 0.05$). Before seeding, almost all fibroblasts were positive for CD90. The lower expression after culture shows that the culture media affected CD90 expression, which has been shown to be related to their phenotypic heterogeneity [60].

The release of the cytokines IL-6 and SCF, which are involved in the differentiation of HSCs to MCs, was measured for fibroblasts. As shown in Figure 4(e), the fibroblasts released IL-6 in a media-dependent manner, with more than two-fold higher release for the cells cultured in StemSpan, compared to the release from fibroblasts cultured in StemPro and HPGM ($p < 0.05$). The expression of SCF gene by fibroblasts has been shown in previous studies [61] and in this work, SCF was released similarly by fibroblasts in all the test media (Figure 4(e)). These data show that fibroblasts can release growth factors, which are necessary for the development and survival of MCs. The concentrations of IL-6 and SCF in the fibroblast culture media were not as high as the concentrations in the HSC media used for MC generation. However, the coculture of fibroblasts with MCs has been shown to upregulate the IL-6 release [62] and may have the same effect on SCF secretion. Besides the effect of soluble factors in the medium, the direct interaction of fibroblasts with MCs was reported to be necessary for MC maturity, inhibition of apoptosis, and generation of MC subtypes specifically found in the connective tissue [63, 64]. Overall, considering the results from testing all of the media, StemSpan was superior for fibroblast culture in a stem cell media.

### 3.4. Effect of Culture Media on Endothelial Cells (ECs)

In contrast with fibroblasts, ECs failed to survive beyond three days in any of the serum-free media (Figure 5(a)). As shown in Figure 5(b), for the serum-supplemented media, ECs showed characteristic, cobblestone-like morphology. The cell yield of ECs was the lowest in HPGM among all the media tested, shown in Figure 5(c). When measuring cell proliferation, the ECs divided at least once in all the culture media in comparison with the control, nondividing cells (solid histogram, Figure 5(d), (i)). ECs cultured in HPGM showed the highest MFI among the other test media, indicating the lowest cell proliferation ($p < 0.05$, Figure 5(d), (ii)). Therefore, HPGM did not support the survival and proliferation of ECs to the extent seen with the other culture media.

The EC phenotypic marker, CD31 [65], was highly expressed for all cells in all the media tested (Figure 5(e), (i) and (ii)), indicating that culture media did not affect the typical EC phenotype.

The release of IL-6 and SCF was also measured for ECs. The release of IL-6 from ECs cultured in StemPro was higher than ECs cultured in StemSpan ($p < 0.05$, Figure 5(f)) and it was not detected from ECs cultured in HPGM (with the ELISA detection limit of 24 pg/ml). Higher levels of IL-6 in StemSpan and StemPro compared to the control media (M199) might be the effect of the media contents or supplements. IL-6 is a cytokine that facilitates the survival and maturation of MCs [66, 67]. In addition to the effect of soluble factors, the direct interaction of adhesion molecules on ECs and c-kit receptors on MCs have been shown to regulate MC survival and the development of connective tissue-type MCs [27]. Although, previous studies have reported the expression of the SCF gene by ECs [68], SCF was not detected in any of the media tested (with the ELISA detection limit of 16 pg/ml). Other studies have shown that SCF was
Figure 4: Effect of serum-free media on fibroblast growth and characteristics. (a) Morphology of fibroblasts at six days postseeding in serum-free media. Arrows show some of the typical fibroblasts. The rest of the experiments were performed ten days postseeding. (b) Fibroblast yield in the culture media. The ratio of the number of collected cells to the number of seeded cells is shown as relative cell yield. (c, (i) and (ii)) Proliferation of fibroblasts in the culture media. Solid histogram shows the cells analyzed on the day of seeding (nondividing cells). (d, (i) and (ii)) Expression of CD90 by fibroblasts in the culture media. Expression of CD90 (open histogram) was compared to an isotype control (solid histogram). (e) Release of SCF and IL-6 by fibroblasts. In all cases, serum-supplemented M199 was taken as the standard cell culture medium. Data are represented as mean ± SD; n = 3. * indicates p < 0.05 between M199 and the test media. † indicates p < 0.05 between the test culture media.
Figure 5: Effect of culture media on endothelial cell (EC) growth and characteristics. (a) Micrographs depicting poor survival of ECs at three days postseeding in serum-free media. Typical detached or dead ECs are highlighted by arrows. (b) Micrographs depicting survival of ECs at six days postseeding in serum-supplemented media. Typical cells are highlighted by arrows. The rest of the experiments were performed 12 days postseeding. (c) EC yields in the serum-supplemented media. Ratio of the number of collected cells to the number of seeded cells is shown as relative cell yield. (d, (i) and (ii)) Proliferation of ECs in the serum-supplemented media. Solid histogram shows the nondividing cells. (e, (i) and (ii)) Expression of CD31 by ECs in the serum-supplemented media. The expression of CD31 (open histogram) was compared to an isotype control (solid histogram). (f) Release of IL-6 by ECs. In all cases, serum-supplemented M199 was taken as the standard cell culture medium. Data are represented as mean ± SD; n = 3. * indicates p < 0.05 between M199 and test media. † indicates p < 0.05 between test culture media.
either not released from ECs, or was released at low levels (e.g., 24.5 ± 1.5 pg/ml) [27, 69]. Taken together, our data suggests that both StemSpan and StemPro supplemented with serum supported EC proliferation and characteristic phenotype.

3.5. Mast Cell (MC) Morphological Phenotype and Function. Considering all the media tested for this study, and specifically focusing on histamine content and immunophenotype of the generated cells, we believe that StemSpan with serum in the last week of culture is the most suitable media for MC development from HSCs. Also, StemSpan supported the ancillary cells. Therefore, the morphological phenotype and function of the cells generated within the matrix in this media after seven weeks in culture were examined. Human MCs are heterogeneous and on the basis of the expression of serine proteases have been classified to tryptase-positive (MC_T), chymase-positive (MC_C), and tryptase- and chymase-positive (MC_TC) MCs [1]. As shown in Figure 6, almost all the generated c-kit-positive cells were expressing tryptase (99.5 ± 0.2%) and chymase (97.1 ± 0.9%) granules, exhibiting the MC_TC phenotype predominant in the skin and small intestinal submucosa [23]. However, when StemSpan was used to generate MCs from CD133+ HSCs in a 2D culture system, the MC_T subtype was observed [16]. This highlights the influence of the microenvironments or culture conditions on the MC phenotype.

Histamine is one of the vasoactive amines in MC granules released upon activation. Sensitization with IgE and activation of the cells with various concentrations of anti-IgE induced substantial degranulation of the cells upon FcεRI cross-linking (Figure 7). The activation of cells removed from the matrix and cells in the matrix resulted in the release of up to 45 ± 3% and 35 ± 3% of the histamine content, respectively, which was about 19-fold higher than the spontaneous histamine release (p < 0.05). Also, Wright-Giemsa staining showed that cells partially or completely lost the metachromatic granules after activation (Figure 7).

In vivo MCs can release less than 10% to more than 40% of the total histamine content in response to the anti-IgE [70–72]. In this work, the generated cells released up to 48% of the histamine content in an anti-IgE concentration-dependent manner, which is comparable to the histamine release from generated MCs in a 2D culture system [15].

The response from the generated cells that were activated either after the removal from the matrix or within the matrix

![Figure 6: Expression of tryptase and chymase by generated cells from CD133+ hematopoietic stem cells (HSCs) in a collagen matrix after seven weeks in culture. StemSpan with serum in the seventh week of culture was used as culture media. Representative density plots and histograms of the marker expression are shown. Expression of tryptase and chymase by c-kit-positive cells (gray histogram) is compared with the isotype control (black histogram).](image1)

![Figure 7: Histamine release by the generated mast cells (MCs) after seven weeks in culture. The cells were activated either within the matrix or after being removed from the matrix. The micrograph shows a few of the degranulated cells activated within the matrix. The white arrow highlights a degranulated MC. In all cases, StemSpan medium with serum in the seventh week of culture was used. Data are represented as mean ± SD; n = 3. All the data are significantly higher than the nonactivated samples (p < 0.05).](image2)
was different with respect to anti-IgE concentration. For the cells that were activated after removal from the matrix, the maximum response was measured for 8 μg/ml anti-IgE, and any further increase of the anti-IgE concentration resulted in a decreased response. For the cells that were activated within the matrix, increasing the anti-IgE concentration up to 200 μg/ml resulted in increased responses, but never reached a maximum response as seen for the cells removed from the matrix. The lower response from the cells within the matrix may be due to the matrix interfering with the binding of IgE and/or anti-IgE with the cells, either due to transport limitations and/or nonspecific binding. In fact, previous studies have shown that other proteins, like monocyte chemoattractant protein-1 (MCP-1), can bind with the matrix and establish a concentration gradient [73, 74]. Therefore, a higher concentration of the IgE antibody was needed to overcome any loss due to the matrix. Nevertheless, the results show that MCs generated within the matrix are functional and release histamine in an IgE-mediated reaction.

4. Conclusion

In this work, we have established that MCs can be generated from HSCs isolated from peripheral blood within a 3D collagen matrix, based on the morphology of the CD133⁺-derived cells, the formation of cytoplasmic granules (histamine), and the expression of MC phenotypic markers (especially c-kit). In addition, according to the same criteria mentioned above, StemSpan with serum added in the last week of culture was the best media to generate functional MCs. StemSpan was also suitable for fibroblast and EC culture. Therefore, we established StemSpan as the ideal media, since it supports the differentiation of HSCs to MCs and phenotypic characteristics of ancillary cells. Furthermore, we determined that serum was not required for fibroblasts, but was required for EC survival and MC maturation during the last week of culture. As a result, to develop the 3D tissue model with all three cell types, fibroblasts and CD133⁺ cells would be seeded in the collagen matrix for six weeks using the serum-free media, then ECs would be added to the apical surface of the matrix in a serum-supplemented media during the seventh week of culture. This work demonstrates the possibility of creating the tissue model that could be used to study the effect of the microenvironmental factors with ancillary cells on MC development and function. However, this study shows that under the influence of microenvironmental factors the morphological and functional characteristics of the cells generated in 3D culture conditions can be altered, as evidenced by differences in their subtype and response to an activating agent when compared with a 2D culture system. The possibility of studying the effect of microenvironmental factors can be considered as the main advantage of utilizing the 3D matrix-embedded cells in elucidating MC ontogeny, biological profile, and immunoregulatory roles.

Data Availability

Data underlying the findings of the study is available upon request to the corresponding author.

Conflicts of Interest

The authors declare no conflict of interest.

Acknowledgments

The authors are grateful to Tabitha Zimmermann and Dr. James H. Meinkoth in the Center for Veterinary Health Sciences for advice on the use of the Wright-Giemsa staining and microscopy, and to Neda Ghousifam in the School of Chemical Engineering for assisting with the cell culture. This work was supported by a grant from the National Science Foundation CAREER Award 1150831.

References

[1] T. C. Moon, C. D. St Laurent, K. E. Morris et al., “Advances in mast cell biology: new understanding of heterogeneity and function,” Mucosal Immunology, vol. 3, no. 2, pp. 111–128, 2010.
[2] L. L. Reber, R. Sibilano, K. Mukai, and S. J. Galli, "Potential effector and immunoregulatory functions of mast cells in mucosal immunity," Mucosal Immunology, vol. 8, no. 3, pp. 444–463, 2015.
[3] Y. A. Mekori and D. D. Metcalfe, "Mast cells in innate immunity," Immunological Reviews, vol. 173, no. 1, pp. 131–140, 2000.
[4] C. E. Brightling, P. Bradding, F. A. Symon, S. T. Holgate, A. J. Wardlaw, and I. D. Pavord, "Mast-cell infiltration of airway smooth muscle in asthma," The New England Journal of Medicine, vol. 346, no. 22, pp. 1699–1705, 2002.
[5] C. K. Andersson, A. Andersson-Sjöland, M. Mori et al., "Activated MCs can activate mast cells in diseased lung areas in cystic fibrosis and idiopathic pulmonary fibrosis," Respiratory Research, vol. 12, no. 1, p. 139, 2011.
[6] S. C. Bischoff, "Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data," Nature Reviews Immunology, vol. 7, no. 2, pp. 93–104, 2007.
[7] T. Hülge, "Beyond allergy: the role of mast cells in fibrosis," Swiss Medical Weekly, vol. 144, article w13999, 2014.
[8] D. Ribatti and G. Ranieri, "Tryptase, a novel angiogenic factor stored in mast cell granules," Experimental Cell Research, vol. 332, no. 2, pp. 157–162, 2015.
[9] T. C. Theoharides, K.-D. Alysandratos, A. Angelidou et al., "Mast cells and inflammation," Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1822, no. 2, pp. 21–33, 2012.
[10] M. Yanagida, H. Fukamachi, K. Ohgami et al., "Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells," Blood, vol. 86, no. 10, pp. 3705–3714, 1995.
[11] P. Valent, E. Spanlächl, W. R. Sperr et al., "Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture," Blood, vol. 80, no. 9, pp. 2237–2245, 1992.
[12] T. Nakahata and H. Toru, "Cytokines regulate development of human mast cells from hematopoietic progenitors," International Journal of Hematology, vol. 75, no. 4, pp. 350–356, 2002.
[13] A. H. Yin, S. Miraglia, E. D. Zanjani et al., “AC133, a novel marker for human hematopoietic stem and progenitor cells,” *Blood*, vol. 90, no. 12, pp. 5002–5012, 1997.

[14] L. E. Sidney, M. J. Branch, S. E. Dunphy, H. S. Dua, and A. Hopkinson, “Concise review: evidence for CD34 as a common marker for diverse progenitors,” *Stem Cells*, vol. 32, no. 6, pp. 1380–1389, 2014.

[15] H. B. Andersen, M. Holm, T. E. Hetland et al., “Comparison of short term in vitro cultured human mast cells from different progenitors—peripheral blood-derived progenitors generate highly mature and functional mast cells,” *Journal of Immunological Methods*, vol. 336, no. 2, pp. 166–174, 2008.

[16] M. Holm, H. B. Andersen, T. E. Hetland et al., “Seven week culture of functional human mast cells from buffy coat preparations,” *Journal of Immunological Methods*, vol. 336, no. 2, pp. 213–221, 2008.

[17] A. Liu, Z. Liu, Z. Li, and Y. Wu, “Molecular regulation of mast cell development and maturation,” *Molecular Biology Reports*, vol. 37, no. 4, pp. 1993–2001, 2010.

[18] H. Ochi, N. H. De Jesus, F. H. Hsieh, K. F. Austen, and J. A. Boyce, “IL-4 and -5 prime human mast cells for different profiles of IgE-dependent cytokine production,” *Proceedings of the National Academy of Sciences*, vol. 97, no. 19, pp. 10509–10513, 2000.

[19] R. Rennick, B. Hunte, G. Holland, and L. Thompson-Snipes, “Cofactors are essential for stem cell factor-dependent growth and maturation of mast cell progenitors: comparative effects of interleukin-3 (IL-3), IL-4, IL-10, and fibroblasts,” *Blood*, vol. 85, no. 1, pp. 57–65, 1995.

[20] C. Dahl, H. Saito, H. V. Nielsen, and P. O. Schistiz, “The establishment of a combined serum-free and serum-supplemented culture method of obtaining functional cord blood-derived human mast cells,” *Journal of Immunological Methods*, vol. 262, no. 1–2, pp. 137–143, 2002.

[21] S. Ishida, T. Kinoshita, N. Sugawara, T. Yamashita, and K. Koike, “Serum inhibitors for human mast cell growth: possible role of retinol,” *Allergy*, vol. 58, no. 10, pp. 1044–1052, 2003.

[22] S. J. Galli, S. Nakae, and M. Tsai, “Mast cells in the development of adaptive immune responses,” *Nature Immunology*, vol. 6, no. 2, pp. 135–142, 2005.

[23] D. D. Metcalfe, D. Baram, and Y. A. Mekori, “Mast cells,” *Physiological Reviews*, vol. 77, no. 4, pp. 1033–1079, 1997.

[24] M. Krystel-Whittemore, K. N. Dileepan, and J. G. Wood, “Mast cell: a multi-functional master cell,” *Frontiers in Immunology*, vol. 6, p. 620, 2016.

[25] C. Oved-Sayer, L. Rapley, T. Mustelin, and D. L. Clarke, “Are mast cells instrumental for fibrotic diseases?,” *Frontiers in Pharmacology*, vol. 4, p. 174, 2013.

[26] A. A. Irani, S. S. Craig, G. Nilsson, T. Ishizaka, and L. B. Schwartz, “Characterization of human mast cells developed in vitro from fetal liver cells cocultured with murine ST3 fibroblasts,” *Immunology*, vol. 77, no. 1, pp. 136–143, 1992.

[27] C. T. Mierke, M. Ballmaier, U. Werner, M. P. Manns, K. Welte, and S. C. Bischoff, “Human endothelial cells regulate survival and proliferation of human mast cells,” *The Journal of Experimental Medicine*, vol. 192, no. 6, pp. 801–812, 2000.

[28] A. M. Dvorak, H. Mitsui, and T. Ishizaka, “Stimulation of partial development of human mast cells by supernatant fluid from mouse fibroblast cultures,” *Clinical Experimental Allergy*, vol. 24, no. 7, pp. 649–659, 1994.

[29] J. L. Gori, J. M. Butler, B. Kumar et al., “Endothelial cells promote expansion of long-term engrafting marrow hematopoietic stem and progenitor cells in primates,” *Stem Cells Translational Medicine*, vol. 6, no. 3, pp. 864–876, 2017.

[30] N. Fujimoto, S. Fujita, T. Tsuji et al., “Microencapsulated feeder cells as a source of soluble factors for expansion of CD34+ hematopoietic stem cells,” *Biomaterials*, vol. 28, no. 32, pp. 4795–4805, 2007.

[31] J. Lappalainen, K. A. Lindstedt, and P. T. Kovanes, “A protocol for generating high numbers of mature and functional human mast cells from peripheral blood,” *Clinical & Experimental Allergy*, vol. 37, no. 9, pp. 1404–1414, 2007.

[32] M. Radinger, B. M. Jensen, H. S. Kuehn, A. Kirshenbaum, and A. M. Gilfillan, “Generation, isolation, and maintenance of human mast cells and mast cell lines derived from peripheral blood or cord blood,” *Current Protocols in Immunology*, 2010, Chapter 7, Unit 7.37.

[33] I. Sukmana and P. Vermette, “The effects of co-culture with fibroblasts and angiogenic growth factors on microvascular maturation and multi-cellular lumen formation in HUVEC-oriented polymer fibre constructs,” *Biomaterials*, vol. 31, no. 19, pp. 5091–5099, 2010.

[34] M. N. Nakatsu, R. C. A. Sainson, J. N. Aoto et al., “Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1,” *Microvascular Research*, vol. 66, no. 2, pp. 102–112, 2003.

[35] S. M. Bauer, R. J. Bauer, Z. J. Liu, H. Chen, L. Goldstein, and O. C. Velazquez, “Vascular endothelial growth factor-C promotes vasculogenesis, angiogenesis, and collagen constriction in three-dimensional collagen gels,” *Journal of Vascular Surgery*, vol. 41, no. 4, pp. 699–707, 2005.

[36] H. Gappa-Fahlenkamp and A. S. Shukla, “The effect of short-term, high glucose concentration on endothelial cells and leukocytes in a 3D in vitro human vascular tissue model,” *In Vitro Cellular & Developmental Biology - Animal*, vol. 45, no. 5-6, pp. 234–242, 2009.

[37] V. Marin, G. Kaplanski, S. Grès, C. Farnarier, and P. Bongrand, “Endothelial cell culture: protocol to obtain and cultivate human umbilical endothelial cells,” *Journal of Immunological Methods*, vol. 254, no. 1–2, pp. 183–190, 2001.

[38] H. Lecoeur, “Nuclear apoptosis detection by flow cytometry: influence of endogenous endonucleases,” *Experimental Cell Research*, vol. 277, no. 1, pp. 1–14, 2002.

[39] E. D. Hsi, *Hematopathology: A Volume in the Series: Foundations in Diagnostic Pathology*, Elsevier/Saunders, Philadelphia, PA, USA, 2nd edition, 2012.

[40] C. Tkaczyk, Y. Okayama, D. D. Metcalfe, and A. M. Gilfillan, “Fcy receptors on mast cells: activatory and inhibitory regulation of mediator release,” *International Archives of Allergy and Immunology*, vol. 133, no. 3, pp. 305–315, 2004.

[41] W. R. Sperr, L. Escriva, J. H. Jordan et al., “Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis,” *Leukemia Research*, vol. 25, no. 7, pp. 529–536, 2001.

[42] E. S. Schulman, A. Kagey-Sobotka, D. W. MacGlashan Jr. et al., “Heterogeneity of human mast cells,” *The Journal of Immunology*, vol. 131, no. 4, pp. 1936–1941, 1983.
[43] L. B. Schwartz, A. M. Irani, K. Roller, M. C. Castells, and N. M. Schechter, “Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells,” The Journal of Immunology, vol. 138, no. 8, pp. 2611–2615, 1987.

[44] R. C. Benyon, M. A. Lowman, and M. K. Church, “Human skin mast cells: their dispersion, purification, and secretory characterization,” The Journal of Immunology, vol. 138, no. 3, pp. 861–867, 1987.

[45] G. M. Gauvreau, A. K. Ellis, and J. A. Denburg, “K. J. Way, H. Dinh, M. R. Keene et al., “Haemopoietic processes in allergic disease: eosinophil/basophil development,” Clinical & Experimental Allergy, vol. 39, no. 9, pp. 1297–1306, 2009.

[46] M. I. Bonetti, S. Bacci, M. Santosuosso et al., “Rosiglitazone promotes the differentiation of Langerhans cells and inhibits that of other dendritic cell types from CD133 positive haemopoietic precursors,” Histology and Histopathology, vol. 29, no. 3, pp. 323–332, 2014.

[47] K. J. Way, H. Dinh, M. R. Keene et al., “The generation and properties of macrophage populations from haemopoietic stem cells,” Journal of Leukocyte Biology, vol. 85, no. 5, pp. 766–778, 2009.

[48] L. Reber, C. A. Da Silva, and N. Frossard, “Stem cell factor and its receptor c-Kit as targets for inflammatory diseases,” European Journal of Pharmacology, vol. 533, no. 1–3, pp. 327–340, 2006.

[49] E. Beutler and W. J. Williams, Williams Hematology, McGraw-Hill, Inc., Health Professions Division, New York, NY, USA, 1995.

[50] H. Agis, W. Füreder, H. C. Bankl et al., “Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes,” Immunology, vol. 87, no. 4, pp. 535–543, 1996.

[51] A. Orfao, L. Escrivan, J. Villarrubia et al., “Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: identification and enumeration,” The American Journal of Pathology, vol. 149, no. 5, pp. 1493–1499, 1996.

[52] A. S. Kirshenbaum, J. P. Goff, T. Semere, B. Foster, L. M. Scott, and D. D. Metcalfe, “Demonstration that human mast cells arise from a progenitor cell population that is CD34+, c-kit+, and expresses aminopeptidase N (CD13),” Blood, vol. 94, no. 7, pp. 2333–2342, 1999.

[53] D. MacGlashan Jr., J. McKenzie-White, K. Chichester et al., “In vitro regulation of FcεR1 expression on human basophils by IgE antibody,” Blood, vol. 91, no. 5, pp. 1633–1643, 1998.

[54] M. Yamaguchi, C. S. Lantz, H. C. Oettgen et al., “IgE enhances mouse mast cell FcεR1 expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions,” The Journal of Experimental Medicine, vol. 185, no. 4, pp. 663–672, 1997.

[55] N. Kambe, M. Kambe, H. W. Chang et al., “An improved procedure for the development of human mast cells from dispersed fetal liver cells in serum-free culture medium,” Journal of Immunological Methods, vol. 240, no. 1-2, pp. 101–110, 2000.

[56] L. Lu, M. Xiao, S. Grigsby et al., “Comparative effects of suppressive cytokines on isolated single CD34(3+) stem/progenitor cells from human bone marrow and umbilical cord blood plated with and without serum,” Experimental Hematology, vol. 21, no. 11, pp. 1442–1446, 1993.

[57] G. L. Gilmore, D. DePasquale, J. Lister, and R. K. Shadduck, “Ex vivo expansion of human umbilical cord blood and peripheral blood CD34+ hematopoietic stem cells,” Experimental Hematology, vol. 28, no. 11, pp. 1297–1305, 2000.

[58] J. M. Sorrell and A. I. Caplan, “Chapter 4. Fibroblasts—a diverse population at the center of it all,” International Review of Cell and Molecular Biology, vol. 276, pp. 161–214, 2009.

[59] L. Kousam, T. J. Smith, S. Feldon, N. Blumberg, and R. P. Phipps, “Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes,” The American Journal of Pathology, vol. 163, no. 4, pp. 1291–1300, 2003.

[60] M. C. Heinrich, D. C. Dooley, A. C. Freed et al., “Constitutive expression of steel factor gene by human stromal cells,” Blood, vol. 82, no. 3, pp. 771–783, 1993.

[61] Y. Montier, A. Lorentz, S. Krämer et al., “Central role of IL-6 and MMP-1 for cross talk between human intestinal mast cells and human intestinal fibroblasts,” Immunobiology, vol. 217, no. 9, pp. 912–919, 2012.

[62] T. Ishizaka, H. Mitsui, M. Yanagida, T. Miura, and A. M. Dvorak, “Development of human mast cells from their progenitors,” Current Opinion in Immunology, vol. 5, no. 6, pp. 937–943, 1993.

[63] G. Sellge, A. Lorentz, T. Gebhardt et al., “Human intestinal fibroblasts prevent apoptosis in human intestinal mast cells by a mechanism independent of stem cell factor, IL-3, IL-4, and nerve growth factor,” Journal of Immunology, vol. 172, no. 1, pp. 260–267, 2004.

[64] C. Garlanda and E. Dejana, “Heterogeneity of endothelial cells. Specific markers,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 7, pp. 1193–1202, 1997.

[65] T. Kikuchi, S. Ishida, T. Kinoshita et al., “IL-6 enhances IgE-dependent histamine release from human peripheral blood-derived cultured mast cells,” Cytokine, vol. 20, no. 5, pp. 200–209, 2002.

[66] H. Saito, M. Ebisawa, H. Tachimoto et al., “Selective growth of human mast cells induced by steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells,” The Journal of Immunology, vol. 157, no. 1, pp. 343–350, 1996.

[67] M. T. Aye, S. Hashemi, B. Leclair et al., “Expression of stem cell factor and c-kit mRNA in cultured endothelial cells, monocytes and cloned human bone marrow stromal cells (CFU-RF),” Experimental Hematology, vol. 20, no. 4, pp. 523–527, 1992.

[68] H. Yamaguchi, E. Ishii, S. Saito et al., “Umbilical vein endothelial cells are an important source of c-kit and stem cell factor which regulate the proliferation of haemopoietic progenitor cells,” British Journal of Haematology, vol. 94, no. 4, pp. 606–611, 1996.

[69] R. C. Benyon, C. Robinson, and M. K. Church, “Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli,” British Journal of Pharmacology, vol. 97, no. 3, pp. 898–904, 1989.

[70] A. M. Dvorak, I. Hammel, E. S. Schulman et al., “Differences in the behavior of cytoplasmic granules and lipid bodies during human lung mast cell degranulation,” The Journal of Cell Biology, vol. 99, no. 5, pp. 1678–1687, 1984.

[71] M. Lowman, P. Rees, R. Benyon, and M. Church, “Human mast cell heterogeneity: histamine release from mast cells
dispersed from skin, lung, adenoids, tonsils, and colon in response to IgE-dependent and nonimmunologic stimuli,” *The Journal of Allergy and Clinical Immunology*, vol. 81, no. 3, pp. 590–597, 1988.

[73] N. Ghousifam, H. Mortazavian, R. Bhowmick, Y. Vasquez, F. D. Blum, and H. Gappa-Fahlenkamp, “A three-dimensional in vitro model to demonstrate the haptotactic effect of monocyte chemoattractant protein-1 on atherosclerosis-associated monocyte migration,” *International Journal of Biological Macromolecules*, vol. 97, pp. 141–147, 2017.

[74] K. Leemasawatdigul and H. Gappa-Fahlenkamp, “Development of a mathematical model to describe the transport of monocyte chemoattractant protein-1 through a three-dimensional collagen matrix,” *Cardiovascular Pathology*, vol. 21, no. 3, pp. 219–228, 2012.